Icosavax, Inc.
Icosavax, Inc. (ICVX): 5 pipeline candidates · ~35 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
35.2 months
D/E 0.08 · 0% dilution
Lead: Phase 2
5 candidates
N/A
N/A
A transparent, data-derived signal for Icosavax, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$63.2M
Quarterly Burn
$19.0M
Runway
35.2 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| ivx-121 | Phase 2 |
| ivx-241 | Phase 2 |
| ivx-411 | Phase 2 |
| ivx-a12 | Phase 2 |
| licensed rsv vaccine | Phase 2 |
Frequently asked questions
How many drug candidates are in Icosavax, Inc.'s pipeline?
Icosavax, Inc. (ICVX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Icosavax, Inc.'s lead drug candidate?
Icosavax, Inc.'s most advanced tracked candidate is ivx-121 (Phase 2) for Respiratory syncytial virus (RSV).
What is Icosavax, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Icosavax, Inc. has approximately 35.2 months of cash runway.
Who is the CEO of Icosavax, Inc.?
Adam Simpson is the chief executive officer of Icosavax, Inc. (ICVX).
Get the full picture on Icosavax, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.